The 340B Drug Pricing Program was designed as a safety net: hospitals serving low-income patients get access to manufacturer drugs at steep discounts — sometimes 25 to 50 percent below list price — and pocket the spread to fund indigent care. What it became is a $50 billion annual subsidy machine that drug companies want to claw back, a federal regulator is trying to restructure, and middlemen like CVS have been quietly monetizing for years. Now the bill is coming due on all three fronts simultaneously.
The mechanism is straightforward. HRSA, which administers 340B, launched a Rebate Model Pilot Program in early 2026 that would shift the discount from an upfront price cut to a post-purchase rebate — a structural change that creates a cash-flow lag for hospitals, advantages manufacturers who can control reimbursement timing, and squeezes the contract-pharmacy relationships that made CVS's specialty pharmacy franchise profitable in the first place. A federal court vacated the pilot in February 2026, but HRSA issued a new Request for Information the same month and HHS has proposed moving 340B oversight from HRSA to CMS — a signal that structural reform is not dead, it is being re-routed.